Most Recent Articles by James Nam, PharmD
Healthy HIV-positive patients with anal cancer are treated with standard chemoradiotherapy, but whether this patient population experiences worse outcomes or more severe toxic effects was previously unknown.
Researchers hypothesized that by reversing the order and administering targeted therapy prior to CN, tumor size would be reduced prior to surgery and lead to improved outcomes.
Researchers tracked the outcomes of 118,543 Swedish patients diagnosed with PCa over a median period of 8.3 years; patients were stratified by characteristics and treatment type.
Researchers randomly assigned 389 patients with R/R CLL who were previously treated with at least 1 but not more than 3 lines of therapy to receive rituximab with venetoclax or bendamustine.
Study results suggest that in all cases, BMI, body weight, WC, and WHR are positively correlated with breast cancer risk.
More Articles by James Nam, PharmD
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Phase 2 Trial of Apatorsen for Metastatic Pancreatic Cancer Misses Primary Endpoint
- Standard Therapy for Anal Cancer May Not Affect Long-term Outcomes Among HIV Patients
- Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs
- Tibetan Yoga May Improve Chemotherapy-related Fatigue
- Sequence of Sunitinib and Nephrectomy May Not Affect Progression-free Rate in mRCC